US Denies Approval for Creat's $1.5 Billion Acquisition of Germany's Biotest

Creat Group of China has withdrawn its current $1.5 billion offer to acquire Biotest, a German blood plasma products corporation, because US regulators refused to approve the deal. According to Bloomberg, the Committee on Foreign Investment in the United States was worried that a China corporation would have access to US donor information. Creat and Biotest said the acquisition can not be completed under the current structure, but the two companies hope to forge a new agreement that will satisfy US regulators. More details.... Stock Symbol: (DE: BIOG) Share this with colleagues: // //